ZA202201154B - Nitenin analogue compounds and their use in the treatment of chronic and acute pain - Google Patents
Nitenin analogue compounds and their use in the treatment of chronic and acute painInfo
- Publication number
- ZA202201154B ZA202201154B ZA2022/01154A ZA202201154A ZA202201154B ZA 202201154 B ZA202201154 B ZA 202201154B ZA 2022/01154 A ZA2022/01154 A ZA 2022/01154A ZA 202201154 A ZA202201154 A ZA 202201154A ZA 202201154 B ZA202201154 B ZA 202201154B
- Authority
- ZA
- South Africa
- Prior art keywords
- nitenin
- treatment
- compounds
- analogue compounds
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT11568519 | 2019-07-31 | ||
| PCT/IB2020/056915 WO2021019373A1 (en) | 2019-07-31 | 2020-07-22 | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202201154B true ZA202201154B (en) | 2024-02-28 |
Family
ID=72240450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/01154A ZA202201154B (en) | 2019-07-31 | 2022-01-25 | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12336977B2 (https=) |
| EP (1) | EP4003984A1 (https=) |
| JP (1) | JP2022544057A (https=) |
| CN (1) | CN114616230A (https=) |
| AU (1) | AU2020320115A1 (https=) |
| CA (1) | CA3149175A1 (https=) |
| IL (1) | IL290192A (https=) |
| MX (1) | MX2022001186A (https=) |
| WO (1) | WO2021019373A1 (https=) |
| ZA (1) | ZA202201154B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4003984A1 (en) | 2019-07-31 | 2022-06-01 | Sea4Us - Biotecnologia e Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
| CN116115739B (zh) * | 2022-12-29 | 2024-01-09 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 胃动素及其受体激动剂的应用 |
| WO2026013449A2 (en) * | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| WO2007009462A2 (en) | 2005-07-15 | 2007-01-25 | Region Hovedstaden V/Glostrup Hospital | Treatment of migraine and headaches |
| ES2345527B1 (es) | 2008-10-08 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima. |
| KR101939401B1 (ko) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물 |
| CN106537149A (zh) * | 2014-04-01 | 2017-03-22 | 宝洁公司 | 用于筛选色氨酸通道的方法 |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| CN106146530A (zh) * | 2015-04-14 | 2016-11-23 | 中国科学院生态环境研究中心 | 一种合成cephalosporolides E,F,H,I的新方法 |
| EP4003984A1 (en) | 2019-07-31 | 2022-06-01 | Sea4Us - Biotecnologia e Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
-
2020
- 2020-07-22 EP EP20761628.5A patent/EP4003984A1/en active Pending
- 2020-07-22 CN CN202080057704.6A patent/CN114616230A/zh active Pending
- 2020-07-22 JP JP2022506029A patent/JP2022544057A/ja active Pending
- 2020-07-22 CA CA3149175A patent/CA3149175A1/en active Pending
- 2020-07-22 AU AU2020320115A patent/AU2020320115A1/en active Pending
- 2020-07-22 MX MX2022001186A patent/MX2022001186A/es unknown
- 2020-07-22 WO PCT/IB2020/056915 patent/WO2021019373A1/en not_active Ceased
- 2020-07-22 US US17/631,135 patent/US12336977B2/en active Active
-
2022
- 2022-01-25 ZA ZA2022/01154A patent/ZA202201154B/en unknown
- 2022-01-27 IL IL290192A patent/IL290192A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3149175A1 (en) | 2021-02-04 |
| IL290192A (en) | 2022-03-01 |
| CN114616230A (zh) | 2022-06-10 |
| AU2020320115A1 (en) | 2022-02-24 |
| WO2021019373A4 (en) | 2021-03-25 |
| US12336977B2 (en) | 2025-06-24 |
| MX2022001186A (es) | 2022-05-11 |
| JP2022544057A (ja) | 2022-10-17 |
| WO2021019373A1 (en) | 2021-02-04 |
| EP4003984A1 (en) | 2022-06-01 |
| US20220288017A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202201154B (en) | Nitenin analogue compounds and their use in the treatment of chronic and acute pain | |
| ZA202104678B (en) | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| MX2023006561A (es) | Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer. | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| WO2018106108A8 (en) | Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain | |
| MX2021008974A (es) | Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof. | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| MX365366B (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| MX2023007080A (es) | Metodo para el tratamiento de la fibrosis. | |
| MX2021005967A (es) | Formas purificadas de rofecoxib, métodos de fabricación y uso. | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| MX2024004319A (es) | Extracto de ca?amo para el tratamiento de dolor, cancer y epilepsia en animales. | |
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| EA202190171A1 (ru) | Применение грамотрицательных видов для лечения атопического дерматита | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| GEAP202215466A (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment | |
| MX2021009535A (es) | Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| MX2022005448A (es) | Método de tratamiento de queratodermia palmoplantar. | |
| PH12023553121A1 (en) | Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient | |
| MX2023005072A (es) | Bloqueo de cd47 y terapias combinadas de los mismos para reducir la inflamacion vascular. | |
| PH12021552326A1 (en) | Combinations of iadademstat for cancer therapy |